Cryptoccocal meningitis and HIV in the era of HAART in Côte d'Ivoire

Medecine et Maladies Infectieuses

Volumn 42, Issue 8, 2012, Pages 349-354

  Aoussi, E F ^a   Ehui, E ^a   Dembele J P ^a   Kolia Diafouka, P ^a   Elloh, N F ^a   Ouattara, S I ^a   Tanon, K A ^a   Doumbia, A ^a   Adou Bryn, K D ^b   Eholie S P ^a   Bissagnene E ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^b Lab de Parasitologie et Mycologie   (Côte d’Ivoire)

Author keywords

Abidjan; Amphotericin B; Cryptococcal meningitis; HAART; HIV

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; FLUCONAZOLE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CONSULTATION; COTE D'IVOIRE; CRYPTOCOCCAL MENINGITIS; FEMALE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LOADING DRUG DOSE; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MORTALITY; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UREMIA; VOMITING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COTE D'IVOIRE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84864612898     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2012.05.012     Document Type: Article

References (33)

1. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 20(23):525-530.
2. Bicanic T., Meintjes G., Rebe K., Williams A., Tech B., Angela A., et al. Immune reconstitution inflammatory syndrome in HIV-Associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009, 51:130-134.
3. Shelburne S.A., Darcourt J., White A.C. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy HIV/AIDS. Clin Infect Dis 2005, 40:1049-1052.
4. Dromer F., Mathoulin-Pellissier S., Launay O., Lortholary O Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D Study. PLoS Med 2007, 4(2):e21. the French Cryptococcosis study Group. 10.1371/journal.pmed.0040021.
5. Lawn S.D., Harries A.D., Anglaret X., et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908.
6. Lewden C., Salmon D., Morlat P., Bevillacqua S., Jougla E., Bonnet F., et al. Causes of deaths among Human Immunodeficiency Virus (HIV) infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005, 34:121-130.
7. Darras-Joly C., Chevret S., Wolff M., et Al Cryptococcus neoformans infection in France: epidemiologic features of early prognostic parameters for 76 patients who were infected with Human Immunodeficiency Virus. Clin Infect Dis 1996, 23:369-376.
8. Eholié S.P., Adou-Brynh K.D., Domoua K., Kakou A., Ehui E., Gouamene A., et al. Méningites lymphocytaires non virales de l'adulte à Abidjan (Côte d'Ivoire). Bull Soc Pathol Exo 2000, 93:50-54.
9. Eholie S.P., Ngbocho L., Bissagnene E., Coulibaly M., Ehui E., Kra O., et al. Mycoses profondes au cours du SIDA à Abidjan (Côte d'Ivoire). Bull Soc Pathol Exot 1997, 90:307-311.
10. Bissagnéné E., Ouhon J., Kra O., Kadio A. Aspects actuels de la cryptococcose neuroméningée à Abidjan. Med Mal Infect 1994, 24; (Suppl 2):580-585. 11-Oumar AA, Dao S, Ba M, Poudiougou B, Diallo A. Epidemiological, clinical and prognostic aspects of cryptococcal meningitis in hospital area of Bamako, Mali. Rev Med Brux 2008, 29:149-152.
11. Oumar A.A., Dao S., Ba M., Poudiougou B., Diallo A. Epidemiological, clinical and prognostic aspects of cryptococcal meningitis in hospital area of Bamako, Mali. Rev Med Brux 2008, 29:149-152.
12. Soumaré M., Seydi M., Ndour C.T., Dieng Y., Diouf A.M., Diop B.M., et al. Aspects actuels de la cryptococcose neuroméningée à Dakar. Med Trop 2005, 65:559-562.
13. Kambugu A., Meya D.B., Rhein J., O'Brien M., Janoff E.N., Ronald A.R., et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008, 46:1694-1701.
14. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill J.R., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
15. Eholié S.P., Tanon K.A., Folquet-Amorissani M., Ouattara I., Aba Y.T., Traoré-Ettiegne V., et al. Lessons from access to antiretroviral therapy in Côte d'Ivoire. Med Trop 2009, 69:520-524.
16. Touré S., Kouadio B., Seyler C., Traoré M., Dakoury-Dogbo N., Duvignac J., et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-years outcomes and determinants. AIDS 2008, 22:873-882.
17. Jarvis J.N., Harrison T.S. HIV-associated cryptococcal meningitis. AIDS 2007, 21:2119-2129.
18. Van Elden L.J., Walenkamp A.M., Lipovsky M.M., Reiss P., Meis J.F., De Marie S., et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000, 14:2787-2800.
19. Lortholary O., Fontanet A., Memain N., et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS 2005, 19:1043-1049.
20. Békondi C., Bernede C., Passone N., Minssart P., Kamalo C., Mbolidi D., et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis 2006, 10:387-395.
21. Hakim J.G., Gangaidzo I.T., Heyderman R.S., Mielke J., Mushangi E., Taziwa A., et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000, 14:1401-1407.
22. Jarvis J.N., Meintjes G., Harrison T.S. Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect 2010, 60:496-498.
23. Lawn S.D., Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther 2011, 9(4):415-430.
24. Keiser O., Anastos K., Schechter M., Balestre E., Myer L., et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008, 13:870-879. ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA).
25. Micol R., Lortholary O., Sar B., Laureillard D., Ngeth C., Dousset J.P., et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007, 45:555-559.
26. Bicanic T., Brouwer A.E., Meintjes G., Rebe K., Limmathurotsakul D., Chierakul W., et al. Relationship of CSF pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009, 23:701-706.
27. Bicanic T., Meintjes G., Wood R., Hayes M., Rebe K., Bekker L.G., et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76-80.
28. Loyse A., Wainwright H., Jarvis J.N., Bicanic T., Rebe K., Meintjes G., et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010, 24:405-410.
29. Brouwer A.E., Rajanuwong A., Chierakul W., Griffin G.E., Larsen R.A., White N.J. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-1767.
30. Nussbaum J.C., Jackson A., Namarika D., Phulusa J., Kenala J., Kanyemba C. Combination flucytosine and high dose fluconazole is superior to fluconazole monotherapy for cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338-344.
31. Makadzange A.T., Ndhlovu C.E., Takarinda K., Reid M., Kurangwa M., Gona P., et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010, 50:1532-1538.
32. Bisson G.P., Nthobatsong R., Thakur R., Lesetedi G., Vinekar K., Tebas P., et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008, 49:227-229.
33. Kadjo A., Ouattara B., Adoubryn K.D., Kra O., Niamkey E.K. Aspects actuels de la cryptococcose chez des adultes infectés par le VIH dans le service de médecine interne du CHU de Treichville d'Abidjan (Côte d'Ivoire). J Mycol Med 2011, 21:6-9.